Dr. Richard Goldberg Joins Real Brands' Board of Directors, Enters Consulting Agreement
Real Brands Inc. (RLBD) has added Dr. Richard Goldberg to its Board of Directors and engaged him in a consulting agreement for guidance in their new Psychedelics research division. Dr. Goldberg, a renowned expert in Psychiatry, will contribute to the development of psychedelic drug therapies. The move marks a significant step in establishing a relationship with a certified medical research facility necessary for securing a psychedelic drug research license from the DEA. The partnership aims to explore the potential of psychedelic therapies in treating psychiatric conditions, leveraging Dr. Goldberg's extensive experience and expertise.
The addition of Dr. Richard Goldberg to Real Brands' Board of Directors and consulting agreement for the Psychedelics research division signifies a strategic move towards advancing research and development in the field of psychedelic drug therapies. Dr. Goldberg's expertise and experience in Psychiatry bring valuable insights and knowledge to the company, positioning Real Brands as a frontrunner in exploring the potential of psychedelic therapies for mental health treatment.
Despite the positive outlook of the partnership with Dr. Goldberg, there may be challenges in navigating the regulatory landscape surrounding psychedelic drug research in the U.S. The process of obtaining a psychedelic drug research license from the DEA could pose hurdles and delays, impacting the timeline for research and development initiatives in this area.
North Providence, RI, May 07, 2024 (GLOBE NEWSWIRE) -- Real Brands Inc. (OTCPK: RLBD) announced today that it has added Richard J. Goldberg, MD, MS, to its Board of Directors, and The Company has entered into a consulting agreement with Dr. Goldberg for guidance and expertise in Real Brand's new Psychedelics research division that was launched in 2023.
Dr. Richard J. Goldberg has joined Real Brands Inc.'s Board of Directors and will consult for them on research and development of psychedelic drug therapies.
"Dr. Goldberg is a renowned, award-winning medical expert in Psychiatry who we are engaging to play a key role in developing strategy and advancing our research and development of psychedelic therapies for the treatment of an array of psychiatric conditions," stated Thom Kidrin, President & CEO of Real Brands Inc. "The Department of Psychiatry that Dr. Goldberg directed attracted millions in grants to fund psychiatric research that has led to significant advances in the understanding and treatment of psychiatric conditions. This is a huge first step In establishing a relationship with a certified medical research facility that is a pre-requisite to receiving a psychedelic drug research license from the DEA."
Dr. Goldberg noted, "There is so much potential in psychedelic therapies that has yet to be explored and harnessed. Thom has a history of pushing the envelope to reshape multiple industries, so it is exciting to work with his team to develop research programs that may lead to improvements in people's mental health. I commend Real Brands for boldly pursuing this frontier and I am pleased to be joining forces with Thom and Real Brands as we explore an area of psychiatric research that has been off-limits in the U.S. until recently."
Dr. Goldberg has been appointed to the highest levels in Psychiatry at premier academic and healthcare institutions, has served on the editorial boards and review committees for the top peer-reviewed Psychiatry medical journals, served on dozens of advisory boards and committees, has founded and led successful healthcare corporations, and has had scores of papers published in peer-reviewed medical journals.
Dr. Goldberg's career highlights include:
- Brown University, Professor, Dept. of Psychiatry and Human Behavior
- Dartmouth Medical School, Adjunct Professor, Dept. of Psychiatry
- Yale University, Director, Program of Behavioral Medicine for Interns
- American Association of General Hospital Psychiatrists, President
- American Association of Geriatric Psychiatry, Chairman, Fellowship Committee
- American Board of Psychiatry and Neurology, Examiner
- Brown University, Editor-in-Chief, Geriatric Psychopharmacology Update
- Psychiatry Foundation of RI, Inc, President & Founder
- The Providence Center for Mental Health Services, Board of Directors and Chair of Long-Range Planning and Patient Care
- State of Rhode Island, Governors Committee on Service and Populations, Statewide Behavioral Health Planning
- Memoir Health, Chief Strategy Officer
- Lumeo Health, Founder and CEO
- Lifespan Healthcare Corporation, Senior Vice President, Psychiatry & Behavioral Health Service Line
- Lifespan Healthcare Corporation, Senior Vice President, Physician Network Development
- National Quality Forum, Mental Health Steering Committee
- Psychiatrist-in-Chief at Rhode Island Hospital, Women & Infants Hospital, and Miriam Hospital
The Business Research Company projects the psychedelic drugs market size will grow at a compound annual growth rate (CAGR) of
# # #
Contacts:
Media Relations: Accentuate PR, Julie Shepherd 847 275 3643, julie@accentuatepr.com
Sales/Investors: 617-725-8900, info@realbrands.com
About Real Brands Inc.
Real Brands is the result of a 2020 merger with Canadian American Standard Hemp Inc. (CASH) that brought together industrial scale hemp CBD oil/isolate extraction and processing, wholesaling of CBD oils and isolate, and production and sales of numerous hemp-derived CBD consumer brands of smokable, edible, and topical products. Its Halo 5 is a proprietary chromatography extraction technology utilizing a Simulated Moving Bed (SMB) that provides the advantage of producing large quantities of highly purified material and precise pharmaceutical grade molecular separation at dramatically reduced costs. Visit www.realbrands.com/ Consumer product lines are available on wabrands.com/, phazesports.com, and americanstandardhemp.com
Follow us on social media:
https://www.linkedin.com/company/real-brands-inc/
https://twitter.com/RealBrandsInc
Forward-Looking Statements
This release contains certain forward-looking statements and information relating to Real Brands, Inc. (the "Company") that are based on the current beliefs of the Company's management, as well as assumptions made by, and information currently available to, the Company. Such statements reflect the current views of the Company with respect to future events and are subject to certain assumptions, including those described in this release. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as "should," "could," "will," "anticipate," "believe," "intend," "plan," "might," "potentially" "targeting" or "expect." Additional factors that could also cause actual results to differ materially are described in our public filings. The Company does not intend to update these forward-looking statements. The content of the websites referenced above are not incorporated herein.
Attachment
FAQ
Who has Real Brands Inc. added to its Board of Directors and engaged in a consulting agreement for the Psychedelics research division?
What is Dr. Richard Goldberg's area of expertise and how will he contribute to Real Brands Inc.?
What is the projected growth of the psychedelic drugs market according to The Business Research Company?
